Management strategies in pancreatic cancer

Christopher J. Campen, Tomislav Dragovich, Amanda F Baker

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Purpose. Current first-line and adjuvant chemotherapeutic strategies for management of patients with pancreatic cancer are reviewed. Summary. Pancreatic adenocarcinoma is the 10th most prevalent cancer and the fourth most common cause of cancer deaths in the United States. More than 80% of patients with pancreatic cancer are diagnosed with locally advanced or metastatic disease and are not candidates for surgery; these patients often require multimodal treatment. The most widely used chemotherapy for such patients, as well as patients requiring adjuvant therapy after surgery, is gemcitabine or gemcitabinebased chemotherapy. All current chemotherapies for pancreatic cancer are associated with dose-limiting hematologic toxicity and other adverse effects that require ongoing monitoring and dosage adjustment to balance the benefits and risks of treatment. Pharmacists can play an important role in monitoring and providing drug information and guidance to patients and oncologists. Current investigational strategies include efforts to improve chemotherapy response rates and outcomes through modulation of cell signaling pathways and use of nanotechnology to improve drug delivery. Conclusion. Current management of pancreatic cancer is multifaceted, involving anticancer therapy, supportive care, and toxicity management. Standard systemic therapy with gemcitabine as a single agent or in combination with other cytotoxic agents provides modest benefits in terms of response and symptom control.

Original languageEnglish (US)
Pages (from-to)573-584
Number of pages12
JournalAmerican Journal of Health-System Pharmacy
Volume68
Issue number7
DOIs
StatePublished - Apr 1 2011

Fingerprint

Pancreatic Neoplasms
gemcitabine
Drug Therapy
Combined Modality Therapy
Nanotechnology
Drug Monitoring
Cytotoxins
Therapeutics
Pharmacists
Cause of Death
Neoplasms
Adenocarcinoma
Pharmaceutical Preparations

Keywords

  • Antineoplastic agents
  • Combined therapy
  • Dosage
  • Drug information
  • Gemcitabine
  • Pancreatic neoplasms
  • Pharmaceutical services
  • Pharmacists
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy

Cite this

Management strategies in pancreatic cancer. / Campen, Christopher J.; Dragovich, Tomislav; Baker, Amanda F.

In: American Journal of Health-System Pharmacy, Vol. 68, No. 7, 01.04.2011, p. 573-584.

Research output: Contribution to journalArticle

Campen, Christopher J. ; Dragovich, Tomislav ; Baker, Amanda F. / Management strategies in pancreatic cancer. In: American Journal of Health-System Pharmacy. 2011 ; Vol. 68, No. 7. pp. 573-584.
@article{197cc3fcc10046fea79d210547adb605,
title = "Management strategies in pancreatic cancer",
abstract = "Purpose. Current first-line and adjuvant chemotherapeutic strategies for management of patients with pancreatic cancer are reviewed. Summary. Pancreatic adenocarcinoma is the 10th most prevalent cancer and the fourth most common cause of cancer deaths in the United States. More than 80{\%} of patients with pancreatic cancer are diagnosed with locally advanced or metastatic disease and are not candidates for surgery; these patients often require multimodal treatment. The most widely used chemotherapy for such patients, as well as patients requiring adjuvant therapy after surgery, is gemcitabine or gemcitabinebased chemotherapy. All current chemotherapies for pancreatic cancer are associated with dose-limiting hematologic toxicity and other adverse effects that require ongoing monitoring and dosage adjustment to balance the benefits and risks of treatment. Pharmacists can play an important role in monitoring and providing drug information and guidance to patients and oncologists. Current investigational strategies include efforts to improve chemotherapy response rates and outcomes through modulation of cell signaling pathways and use of nanotechnology to improve drug delivery. Conclusion. Current management of pancreatic cancer is multifaceted, involving anticancer therapy, supportive care, and toxicity management. Standard systemic therapy with gemcitabine as a single agent or in combination with other cytotoxic agents provides modest benefits in terms of response and symptom control.",
keywords = "Antineoplastic agents, Combined therapy, Dosage, Drug information, Gemcitabine, Pancreatic neoplasms, Pharmaceutical services, Pharmacists, Toxicity",
author = "Campen, {Christopher J.} and Tomislav Dragovich and Baker, {Amanda F}",
year = "2011",
month = "4",
day = "1",
doi = "10.2146/ajhp100254",
language = "English (US)",
volume = "68",
pages = "573--584",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "7",

}

TY - JOUR

T1 - Management strategies in pancreatic cancer

AU - Campen, Christopher J.

AU - Dragovich, Tomislav

AU - Baker, Amanda F

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Purpose. Current first-line and adjuvant chemotherapeutic strategies for management of patients with pancreatic cancer are reviewed. Summary. Pancreatic adenocarcinoma is the 10th most prevalent cancer and the fourth most common cause of cancer deaths in the United States. More than 80% of patients with pancreatic cancer are diagnosed with locally advanced or metastatic disease and are not candidates for surgery; these patients often require multimodal treatment. The most widely used chemotherapy for such patients, as well as patients requiring adjuvant therapy after surgery, is gemcitabine or gemcitabinebased chemotherapy. All current chemotherapies for pancreatic cancer are associated with dose-limiting hematologic toxicity and other adverse effects that require ongoing monitoring and dosage adjustment to balance the benefits and risks of treatment. Pharmacists can play an important role in monitoring and providing drug information and guidance to patients and oncologists. Current investigational strategies include efforts to improve chemotherapy response rates and outcomes through modulation of cell signaling pathways and use of nanotechnology to improve drug delivery. Conclusion. Current management of pancreatic cancer is multifaceted, involving anticancer therapy, supportive care, and toxicity management. Standard systemic therapy with gemcitabine as a single agent or in combination with other cytotoxic agents provides modest benefits in terms of response and symptom control.

AB - Purpose. Current first-line and adjuvant chemotherapeutic strategies for management of patients with pancreatic cancer are reviewed. Summary. Pancreatic adenocarcinoma is the 10th most prevalent cancer and the fourth most common cause of cancer deaths in the United States. More than 80% of patients with pancreatic cancer are diagnosed with locally advanced or metastatic disease and are not candidates for surgery; these patients often require multimodal treatment. The most widely used chemotherapy for such patients, as well as patients requiring adjuvant therapy after surgery, is gemcitabine or gemcitabinebased chemotherapy. All current chemotherapies for pancreatic cancer are associated with dose-limiting hematologic toxicity and other adverse effects that require ongoing monitoring and dosage adjustment to balance the benefits and risks of treatment. Pharmacists can play an important role in monitoring and providing drug information and guidance to patients and oncologists. Current investigational strategies include efforts to improve chemotherapy response rates and outcomes through modulation of cell signaling pathways and use of nanotechnology to improve drug delivery. Conclusion. Current management of pancreatic cancer is multifaceted, involving anticancer therapy, supportive care, and toxicity management. Standard systemic therapy with gemcitabine as a single agent or in combination with other cytotoxic agents provides modest benefits in terms of response and symptom control.

KW - Antineoplastic agents

KW - Combined therapy

KW - Dosage

KW - Drug information

KW - Gemcitabine

KW - Pancreatic neoplasms

KW - Pharmaceutical services

KW - Pharmacists

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=79956008277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956008277&partnerID=8YFLogxK

U2 - 10.2146/ajhp100254

DO - 10.2146/ajhp100254

M3 - Article

C2 - 21411798

AN - SCOPUS:79956008277

VL - 68

SP - 573

EP - 584

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 7

ER -